Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer
Status:
Completed
Trial end date:
2018-03-20
Target enrollment:
Participant gender:
Summary
This study will be looking at the objective response rate (ORR) as measured by RECIST in in
patients with mismatch repair-proficient (MMR-p), advanced colorectal cancer that treated
with CY/GVAX in combination with Pembrolizumab.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins